Cisplatin and the sensitive cell

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Epigenetic suppression of FANCF, a member of the Fanconi anemia gene family, is now implicated in some ovarian cancers. Might this suppression explain the sensitivity of such cancers to the cross-linking agent cisplatin (pages 568-574)?

Original languageEnglish (US)
Pages (from-to)513-514
Number of pages2
JournalNature Medicine
Volume9
Issue number5
DOIs
StatePublished - May 1 2003
Externally publishedYes

Fingerprint

Fanconi Anemia
Epigenomics
Ovarian Neoplasms
Cisplatin
Genes
Neoplasms

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Cisplatin and the sensitive cell. / Bagby, Grover C.; Olson, Susan.

In: Nature Medicine, Vol. 9, No. 5, 01.05.2003, p. 513-514.

Research output: Contribution to journalArticle

@article{d4038b5a8ec243fd8600070b0efbeba4,
title = "Cisplatin and the sensitive cell",
abstract = "Epigenetic suppression of FANCF, a member of the Fanconi anemia gene family, is now implicated in some ovarian cancers. Might this suppression explain the sensitivity of such cancers to the cross-linking agent cisplatin (pages 568-574)?",
author = "Bagby, {Grover C.} and Susan Olson",
year = "2003",
month = "5",
day = "1",
doi = "10.1038/nm0503-513",
language = "English (US)",
volume = "9",
pages = "513--514",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Cisplatin and the sensitive cell

AU - Bagby, Grover C.

AU - Olson, Susan

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Epigenetic suppression of FANCF, a member of the Fanconi anemia gene family, is now implicated in some ovarian cancers. Might this suppression explain the sensitivity of such cancers to the cross-linking agent cisplatin (pages 568-574)?

AB - Epigenetic suppression of FANCF, a member of the Fanconi anemia gene family, is now implicated in some ovarian cancers. Might this suppression explain the sensitivity of such cancers to the cross-linking agent cisplatin (pages 568-574)?

UR - http://www.scopus.com/inward/record.url?scp=0037954561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037954561&partnerID=8YFLogxK

U2 - 10.1038/nm0503-513

DO - 10.1038/nm0503-513

M3 - Article

C2 - 12724761

AN - SCOPUS:0037954561

VL - 9

SP - 513

EP - 514

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

IS - 5

ER -